Clinical Trials
295
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (192 trials with phase data)• Click on a phase to view related trials
Efficacy and Safety Evaluation of Non-invasive Temporal Interference Stimulation for Blood Pressure Regulation
- Conditions
- HypertensionHypotension
- First Posted Date
- 2025-11-20
- Last Posted Date
- 2025-11-20
- Lead Sponsor
- Xuanwu Hospital, Beijing
- Target Recruit Count
- 25
- Registration Number
- NCT07239492
- Locations
- 🇨🇳
Xuanwu Hospital,Capital Medical University, Beijing, Beijing 100053, Beijing, China
Transcranial Alternating Current Stimulation for Patients With Mild Alzheimer's Disease II (TRANSFORM-AD II)
- Conditions
- Alzheimer Disease
- First Posted Date
- 2025-11-17
- Last Posted Date
- 2025-11-17
- Lead Sponsor
- Xuanwu Hospital, Beijing
- Target Recruit Count
- 160
- Registration Number
- NCT07230158
- Locations
- 🇨🇳
Xuanwu Hospital, Capital Medical University, Beijing, Beijing Municipality, China
Personalized Brain Stimulation for Cognitive Impairment in Older Adults
- Conditions
- Alzheimer s Disease
- First Posted Date
- 2025-10-06
- Last Posted Date
- 2025-10-06
- Lead Sponsor
- Xuanwu Hospital, Beijing
- Target Recruit Count
- 460
- Registration Number
- NCT07208734
- Locations
- 🇨🇳
Xuanwu Hospital, Capital Medical University, Beijing, Beijing 100053, Beijing, Beijing Municipality, China
Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours
- Conditions
- Acute Ischemic StrokeBasilar Artery Occlusion
- Interventions
- Drug: Tenecteplase thrombolysis
- First Posted Date
- 2025-10-02
- Last Posted Date
- 2025-10-02
- Lead Sponsor
- Xuanwu Hospital, Beijing
- Target Recruit Count
- 506
- Registration Number
- NCT07203625
- Locations
- 🇨🇳
Xuanwu Hospital, Capital Medical University, Beijing, China
Sodium Sivelestat With Mechanical Thrombectomy for Acute Stroke: A Pilot Study
- Conditions
- Acute Ischemic StrokeNeutrophil Extracellular Traps FormationLarge Vessel OcclusionThrombectomy
- Interventions
- Drug: Sodium Sivelestat
- First Posted Date
- 2025-09-29
- Last Posted Date
- 2025-09-29
- Lead Sponsor
- Xuanwu Hospital, Beijing
- Target Recruit Count
- 20
- Registration Number
- NCT07196605
- Locations
- 🇨🇳
Xuanwu Hospital, Capital Medical University., Beijing, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 59
- Next
News
METiS TechBio's AI-Designed Drug MTS-004 Becomes First in China to Complete Phase III Trial for Pseudobulbar Affect
MTS-004 has become China's first AI-enabled formulation drug candidate to successfully complete Phase III clinical trials, marking a significant milestone in AI-driven pharmaceutical development.